Sunday, July 27, 2014 5:38:50 PM
Hum Gene Ther Methods. 2014 Jul 21. [Epub ahead of print]
Targeting both viral and host determinants of HIV entry using a new lentiviral vector co-expressing the T20 fusion inhibitor and a selective CCL5 intrakine.
Petit NY1, Dorgham K, Bault B, Burlion A, Gorochov G, Marodon G.
Author information
1CIMI, INSERM U1135, PARIS, France ; nicolas.petit1984@gmail.com.
Abstract
Numerous strategies targeting early and late steps of the HIV life cycle have been proposed for gene therapy. However, targeting viral and hosts determinants of HIV entry is the only strategy that would prevent viral DNA-mediated CD4 cell death while diminishing the possibility for the virus to escape. To this end, we devised a bicistronic lentiviral vector expressing the membrane bound form of the T20 fusion inhibitor, referred to as the C46 peptide, and a CCR5 super-agonist, modified to sequester CCR5 away from the cell surface, referred to as the P2-CCL5 intrakine. We tested the effects of the vector on HIV infection and replication using the human CEMR5 cell line expressing CD4 and CCR5 and on primary human T cells. Transduced cells expressed the C46 peptide, detected with the 2F5 monoclonal antibody by flow cytometry. Expression of the P2-CCL5 intrakine correlates with lower levels of cell surface CCR5. Complete protection to HIV infection could be observed in cells expressing the protective transgenes. Importantly, we show that the combination of the transgenes was more potent than single transgene alone, showing the interest of expressing two entry inhibitors to inhibit HIV infection. Finally, genetically modified cells possessed a selective advantage over non-modified cells upon HIV challenge in vitro, showing that modified cells were protected from HIV-induced cell death. Our results demonstrate that lentiviral vectors co-expressing the T20 fusion inhibitor and the P2-CCL5 intrakine represent promising tools for HIV gene therapy.
Good luck and GOD bless,
George
Recent BNTC News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/29/2024 08:28:27 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 07/19/2024 08:59:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 09:18:32 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2024 02:22:02 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/29/2024 08:32:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 12:05:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 12:01:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:17:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:13:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:12:19 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 02/26/2024 02:06:56 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/23/2024 09:09:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 01:15:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 01:01:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:15:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/30/2023 12:31:00 PM
- Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference • GlobeNewswire Inc. • 11/17/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:03:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:00:49 PM
- Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/20/2023 08:31:26 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/20/2023 10:04:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:29:59 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM